Clinical Trials

It is estimated only 2%–3% of adult cancer patients participate in clinical trials(1). Historically, women, racial/ethnic minorities, and economically-disadvantaged adults have been underrepresented in clinical trials. Factors that contribute to this disparity include the unavailability of clinical trials at treating sites, financial strains due to increased visits, social barriers (i.e., transportation and childcare), lack of knowledge (of clinical trials) among physicians, and lack of awareness among patients. (2)

Access to and participation in clinical trials ensures patients are offered cutting-edge therapies that aim to improve the prevention, diagnosis, and treatment of cancer.  The BRIDGE program facilitates world-class care to residents of Brooklyn and Queens who are faced with a blood cancer diagnosis by mitigating barriers that may prevent them from enrolling or staying on a clinical trial.

Icon of money in an envelope – representing staffing and financial support Financial Support 

The program provides financial support to offset excess costs for participating in clinical trials.

Icon of group of dark orange individuals – representing raising awareness and education Patient Navigation

Patient navigators are specifically trained to assist patients with their treatment decisions, as well as educating patients on the benefits of clinical trials as a critical treatment option.

Icon of two hands, orange and yellow, grasped in a shaking motion – representing clinical treatment decision support Decision Navigation Intervention

A decision aid administered by our patient navigators that empowers cancer patients to prepare for and actively participate in medical consultations and treatment decision appointments after a positive biopsy or laboratory study confirming a cancer diagnosis

 

Here is a list of available studies at our sites for patients who have been diagnosed with a blood cancer:

Lymphoma

The Lymphoma Epidemiology of Outcomes (LEO) Cohort Study Protocol

Multiple Myeloma

A Phase II Study of Daratumumab, Clarithromycin, Pomalidomide, and Dexamethasone (D-ClaPd) In Multiple Myeloma Patients Previously Exposed to Daratumumab

Weill Cornell Medicine BRIDGE Program 1300 York Avenue New York, NY 10065 Phone: (929) 470-9410